Giansun Precision Technology Group
001400
Heilongjiang Tianyouwei Electronics
603202
Joy Kie Corporation
300994
4
Kingchem
301509
5
Hunan Er-kang Pharmaceutical
300267
CN Stock MarketDetailed Quotes
002793 Luoxin Pharmaceuticals Group Stock
- 4.72
- +0.43+10.02%
Not Open Apr 24 15:00 CST
5.13BMarket Cap-5.56P/E (TTM)
4.72High4.30Low584.46KlotVolume4.30Open4.29Pre Close270.46MTurnover5.38%Turnover RatioLossP/E (Static)1.09BShares5.3252wk High3.68P/B5.13BFloat Cap3.2252wk Low4.72Limit Up1.09BShs Float27.94Historical High3.86Limit Down9.79%Amplitude3.22Historical Low--Dividend TTM4.63Avg Price285.88KlotAsk--Div YieldTTM100Lot Size283.76KlotBid
Luoxin Pharmaceuticals Group Stock Key Stats
All
YOY
| (Q3)Mar 31, 2025 | (FY)Dec 31, 2024 | (Q9)Sep 30, 2024 | (Q6)Jun 30, 2024 | (Q3)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q9)Sep 30, 2023 | (Q6)Jun 30, 2023 | (Q3)Mar 31, 2023 | (FY)Dec 31, 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total operating revenue | -29.91%482.73M | 11.99%2.65B | 2.98%1.88B | 0.30%1.26B | 3.97%688.73M | -34.11%2.36B | -51.55%1.83B | -60.05%1.26B | -69.57%662.43M | -44.62%3.59B |
| Operating revenue | -29.91%482.73M | 11.99%2.65B | 2.98%1.88B | 0.30%1.26B | 3.97%688.73M | -34.11%2.36B | -51.55%1.83B | -60.05%1.26B | -69.57%662.43M | -44.62%3.59B |
| Other operating revenue | ---- | -7.31%32.7M | ---- | -23.82%19.47M | ---- | -70.01%35.27M | ---- | -56.10%25.55M | ---- | 8.60%117.61M |
| Total operating cost | -30.85%510.26M | 11.07%3.11B | 5.58%2.16B | -2.03%1.39B | -1.97%737.87M | -46.29%2.8B | -52.49%2.05B | -55.96%1.42B | -61.97%752.69M | -12.26%5.22B |
| Operating cost | -40.47%259.73M | 20.61%1.53B | 11.51%1.08B | 14.18%753M | 22.91%436.3M | -51.68%1.27B | -56.33%964.73M | -57.24%659.49M | -60.08%354.97M | -18.55%2.63B |
| Operating tax surcharges | -3.05%4.88M | -1.76%20.87M | -2.69%13.78M | 16.67%9.67M | 22.04%5.03M | -47.72%21.25M | -57.26%14.16M | -66.75%8.29M | -73.56%4.12M | -45.43%40.64M |
| Operating expense | -25.17%152.63M | 18.39%1.14B | 11.72%766.65M | -8.46%442.58M | -18.01%203.98M | -44.28%964.01M | -53.61%686.2M | -61.73%483.46M | -72.29%248.78M | -7.31%1.73B |
| Administration expense | -9.23%57.74M | -26.05%276.44M | -10.83%213.64M | -20.68%126.98M | -25.25%63.61M | -25.08%373.84M | -24.63%239.6M | -23.87%160.09M | -14.19%85.1M | 35.88%498.97M |
| Financial expense | 33.13%18.1M | -9.55%57.3M | -17.00%43.77M | -38.63%28.53M | -34.75%13.6M | -46.74%63.35M | -47.64%52.74M | -20.78%46.49M | 1.53%20.84M | 24.29%118.95M |
| -Interest expense (Financial expense) | 5.63%15.69M | -15.26%64.38M | -24.13%47.21M | -34.30%30.78M | -39.19%14.86M | -38.07%75.97M | -33.88%62.22M | -15.78%46.86M | 2.09%24.43M | 16.63%122.67M |
| -Interest Income (Financial expense) | 69.42%-389.34K | 32.29%-6.3M | 66.19%-3.02M | 61.45%-2.38M | 5.87%-1.27M | 36.58%-9.3M | 15.45%-8.93M | 27.79%-6.16M | 67.78%-1.35M | -48.64%-14.66M |
| Research and development | 11.93%17.18M | -22.14%87.41M | -46.03%49.21M | -51.42%30.06M | -60.53%15.35M | -45.16%112.27M | -46.92%91.17M | -50.10%61.88M | -31.86%38.89M | -36.21%204.73M |
| Credit Impairment Loss | 4,433.56%41.2M | 74.32%-14.12M | 109.09%2.24M | 318.86%9.59M | -64.11%908.76K | -176.45%-54.97M | 71.49%-24.6M | 95.86%-4.38M | 102.47%2.53M | 79.51%-19.88M |
| Asset Impairment Loss | -20.75%-2.48M | -140.28%-300.72M | -10.22%-34.8M | -121.14%-12.24M | 89.53%-2.06M | -72.24%-125.15M | -858.86%-31.57M | -335.04%-5.53M | -1,748.05%-19.63M | -1,184.54%-72.66M |
| Other net revenue | 992.55%43.33M | -236.91%-490.88M | 53.81%-16.64M | 51.18%12.59M | 141.26%3.97M | -183.27%-145.7M | -346.63%-36.03M | 167.00%8.33M | 89.96%-9.61M | 450.98%174.96M |
| Fair value change income | ---- | -5,166.53%-213.13M | ---- | ---- | ---- | -301.05%-4.05M | ---- | ---- | ---- | 179.16%2.01M |
| Invest income | -55.90%-3.41M | -122.23%-3.45M | -918.53%-12.34M | -284.45%-6.64M | -185.09%-2.19M | -90.38%15.54M | 27.91%1.51M | 857.11%3.6M | 4,610.20%2.57M | 22,694.40%161.58M |
| -Including: Investment income associates | -55.09%-3.41M | -81.82%2.88M | -1,023.65%-12.48M | -289.66%-6.65M | -187.53%-2.2M | 1,671.63%15.85M | --1.35M | --3.51M | --2.51M | --894.93K |
| Asset deal income | -272.92%-51.24K | 101.98%240.87K | -106.81%-114.12K | -106.94%-133.6K | -106.42%-13.74K | -801.54%-12.18M | 469.04%1.68M | 31,490.48%1.93M | --214.07K | 152.47%1.74M |
| Other revenue | 10.36%8.07M | 14.77%40.3M | 67.27%28.37M | 72.96%22.01M | 55.32%7.31M | -65.64%35.11M | -81.81%16.96M | -85.57%12.72M | -19.27%4.71M | 71.92%102.18M |
| Operating profit | 134.96%15.79M | -63.43%-958.5M | -15.67%-298.56M | 23.68%-118.99M | 54.77%-45.17M | 59.80%-586.48M | 51.09%-258.11M | -67.53%-155.91M | -197.87%-99.88M | -406.01%-1.46B |
| Add:Non operating Income | -55.53%275.37K | -36.78%13.07M | -43.16%9.86M | -15.91%9.42M | -78.66%619.25K | 596.80%20.68M | 613.76%17.35M | 660.31%11.21M | 190.02%2.9M | -81.16%2.97M |
| Less:Non operating expense | -83.64%88.86K | -80.61%7.43M | -40.80%2.64M | -53.09%714.87K | -27.21%543.01K | 449.34%38.32M | -50.21%4.46M | -68.89%1.52M | -66.92%745.96K | -4.64%6.98M |
| Total profit | 135.43%15.98M | -57.73%-952.85M | -18.81%-291.33M | 24.58%-110.28M | 53.85%-45.1M | 58.71%-604.11M | 54.10%-245.21M | -51.55%-146.23M | -196.95%-97.72M | -401.51%-1.46B |
| Less:Income tax cost | 205.03%13.83M | -39.68%99.4M | -36.51%26.27M | -28.13%11.12M | -21.57%4.53M | 180.14%164.81M | 181.67%41.37M | 25.98%15.47M | -62.57%5.78M | -423.57%-205.64M |
| Net profit | 104.33%2.15M | -36.85%-1.05B | -10.82%-317.6M | 24.92%-121.39M | 52.05%-49.63M | 38.84%-768.92M | 40.74%-286.58M | -48.66%-161.69M | -221.27%-103.5M | -398.19%-1.26B |
| Net profit from continuing operation | 104.37%2.15M | -35.98%-1.05B | -9.35%-315.55M | 26.90%-119.34M | 52.09%-49.17M | 48.09%-773.8M | 40.33%-288.57M | -50.11%-163.27M | -220.24%-102.62M | -453.55%-1.49B |
| Net income from discontinuing operating | ---- | ---- | -202.87%-2.05M | -230.53%-2.05M | 47.27%-463.28K | -97.91%4.89M | --1.99M | --1.57M | ---878.55K | --233.41M |
| Less:Minority Profit | 72.98%-3.5M | 19.50%-86.76M | 8.48%-52.23M | 6.10%-32.68M | 2.23%-12.97M | -232.98%-107.78M | -514.72%-57.07M | -473.18%-34.81M | -461.80%-13.27M | -308.16%-32.37M |
| Net profit of parent company owners | 115.41%5.65M | -46.04%-965.5M | -15.62%-265.37M | 30.09%-88.71M | 59.37%-36.66M | 46.03%-661.14M | 53.85%-229.51M | -7.44%-126.89M | -210.47%-90.24M | -401.63%-1.22B |
| Earning per share | ||||||||||
| Basic earning per share | 133.33%0.01 | -49.18%-0.91 | -19.05%-0.25 | 33.33%-0.08 | 62.50%-0.03 | 29.07%-0.61 | 38.24%-0.21 | -50.00%-0.12 | -233.33%-0.08 | -407.14%-0.86 |
| Diluted earning per share | 133.33%0.01 | -47.54%-0.9 | -19.05%-0.25 | 33.33%-0.08 | 62.50%-0.03 | 29.07%-0.61 | 38.24%-0.21 | -50.00%-0.12 | -233.33%-0.08 | -407.14%-0.86 |
| Other composite income | -104.08%-53.8K | 132.75%676.11K | -96.40%212.67K | -83.20%2.19M | 139.13%1.32M | -107.89%-2.06M | -82.55%5.9M | -10.53%13.06M | 50.67%-3.37M | 1,682.57%26.17M |
| Other composite income of parent company owners | -104.08%-53.61K | 132.75%673.78K | -96.40%211.93K | -83.20%2.19M | 139.13%1.31M | -107.89%-2.06M | -82.55%5.88M | -10.53%13.01M | 50.67%-3.36M | 1,682.57%26.07M |
| Other composite income of minority owners | -104.08%-185.74 | 132.75%2.33K | -96.40%734.21 | -83.20%7.57K | 139.13%4.55K | -107.89%-7.13K | -82.55%20.37K | -10.53%45.08K | 50.67%-11.63K | 1,682.57%90.33K |
| Total composite income | 104.33%2.09M | -36.40%-1.05B | -13.08%-317.39M | 19.80%-119.2M | 54.79%-48.31M | 37.38%-770.98M | 37.60%-280.68M | -57.83%-148.64M | -236.11%-106.87M | -393.13%-1.23B |
| Total composite income of parent company owners | 115.84%5.6M | -45.48%-964.82M | -18.57%-265.16M | 24.02%-86.52M | 62.23%-35.35M | 44.68%-663.2M | 51.77%-223.63M | -9.97%-113.87M | -225.00%-93.59M | -396.42%-1.2B |
| Total composite income of minority owners | 72.97%-3.5M | 19.51%-86.76M | 8.45%-52.23M | 6.00%-32.68M | 2.35%-12.97M | -233.93%-107.79M | -511.09%-57.05M | -470.69%-34.76M | -464.46%-13.28M | -307.65%-32.28M |
| Currency Unit | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY |
| Accounting Standards | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) |
| Audit Opinions | -- | Unqualified opinion | -- | -- | -- | Unqualified opinion | -- | -- | -- | Unqualified opinion |
| Auditor | -- | Tianjian Certified Public Accountants (Special General Partnership) | -- | -- | -- | Tianjian Certified Public Accountants (Special General Partnership) | -- | -- | -- | Tianjian Certified Public Accountants (Special General Partnership) |
FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.
Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.